A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 448 participants.

Also called NCT06542874

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 448 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT06542874
Other papers using this trial's data
  • Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial Lancet (London, England), 2026-08-15 DOI, PubMed 42532079 PubMed links an erratum for this paper. Erratum: PMID 42913681
  • Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial Lancet (London, England), 2026-08-15 DOI, PubMed 42532080

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Bulgaria, Croatia, Germany, Greece, Hungary, Japan, Poland, Romania, Slovakia, Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06542874. Randomized; quadruple masking; primary purpose treatment. Start 2024-08-07 (actual); primary completion 2025-10-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes
Condition
Type 2 Diabetes (T2D)
Intervention (Drug)
NNC0487-0111 subcutanous
Intervention (Drug)
Placebo (NNC0487-0111 subcutanous)
Intervention (Drug)
NNC0487-0111 oral
Intervention (Drug)
Placebo (NNC0487-0111 oral)
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct06542874
Content hash
f86e9df47a47e18b089b49e456dc558850d875d62be4a52bf5593a97f462d6ab